<DOC>
	<DOCNO>NCT01406587</DOCNO>
	<brief_summary>PP4001 medication yet approve US FDA . This phase 2 , multi-center , randomize , double-blind study 3 dos PP4001 versus placebo treatment symptom associate uncomplicated urinary tract infection . After screen , patient randomize receive one three dos PP4001 placebo . Patients screen randomized day , take 4 dos study drug , one dose every 12 hour . Data uncomplicated urinary tract infection symptom collect subject electronic handheld device throughout 48-hour study period . The primary endpoint burn urination .</brief_summary>
	<brief_title>Safety Efficacy PP4001 Treatment Symptoms Associated With Uncomplicated Urinary Tract Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<criteria>Female subject must ≥ 18 ≤ 75 year age time consent . Females childbearing potential ( FNCBP ) eligible randomization . FNCBP define postmenopausal woman last menstrual cycle ( without exogenous hormone therapy ) complete 12 consecutive month screen woman surgically sterilize ( hysterectomy , oophorectomy , tubal ligation ) . Females childbearing potential also eligible randomization provide pregnant nursing employ appropriate method contraceptive duration trial . Medically acceptable form contraception include abstinence , oral contraceptive , intrauterine device , injectable hormonals , intravaginal ring , doublebarrier method ( condom plus spermicide ) , least 1 month prior treatment . Subjects monogamous , long term relationship partner vasectomy least 3 month prior screen also study eligible . Diagnosis uncomplicated UTI define follow : Presence support symptom include new onset ( within 1 week ) urination frequency , painful urination , and/or urgency . Positive dipstick test leukocyte esterase . Demonstration moderate severe burn urination measure score least six ( 6 ) 11point rating scale Burning During Urination screen . A negative urine pregnancy test woman childbearing potential . If subject chronic , clinically stable disease require medication , medication treat disease must stable least 30 day prior screen . Ability perform study procedure , include completion electronic diary assessment , supply necessary information study personnel require protocol . A sign informed consent form subject agree participate study fully explain . Clinically significant medical history clinically significant abnormal find physical exam , vital sign ECG screening , include serious acute illness ( e.g . pneumonia ) , gastrointestinal illness would interfere study drug absorption , untreated unstable medical illness would likely interfere study assessment . At risk term precaution , warning , contraindication package insert phenazopyridine hydrochloride include : Known hypersensitivity phenazopyridine hydrochloride ( Defined history allergic adverse response drug ) . Renal failure insufficiency ( Defined history abnormal renal function know renal disease ) . History hepatic disease failure ( Defined know liver disease elevate LFTs ( &gt; 2 time ULN ) previous laboratory test . Patients would otherwise test require undergo special study lab ) . Known G6PD ( glucose6phosphate dehydrogenase ) deficiency . Prior use phenazopyridine product within 6 month first dose study drug throughout study . Use prescription analgesic medication ( e.g . opioids , prescription nonsteroidal antiinflammatory drug ( NSAID ) , etc . ) urinary tract pain pain ( headache , back pain , joint pain , dental pain , sore muscle , etc ) within one half ( 1.5 ) dosing interval medication fir dose study drug , throughout study . Use systemic antibiotic within seven ( 7 ) day study participation . Subjects complaint abnormal vaginal discharge . Current diagnosis suspicion complicate UTI systemic infection base one following : Known presence anatomic functional abnormality . Presence urinary catheter . Infection urinary tract require intravenous pyelogram ( IVP ) , ultrasound cystoscopy . Clinical sign systemic infection fever ( oral tympanic temperature &gt; 38 degree Celsius ) , costovertebral pain tenderness , rigor , nausea vomit . Subjects unable comprehend language inform consent self evaluation scale . Subjects , opinion investigator , appropriate , unable , unwilling undergo antibiotic treatment uncomplicated urinary tract infection . Subjects complaint abnormal vaginal bleeding define different patient 's usual menstrual period flow timing . Subjects know allergy multivitamin component multivitamin . Currently participate clinical trial receive experimental drug use experimental device last 30 day prior admission study . Subjects , opinion investigator , unsuitable enrollment , unlikely complete course study medication treatment , unlikely attend End Study visit . Subjects unable unwilling comply use electronic subject diary . Employees investigator institution direct involvement trial trial direction investigator associate .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Burning</keyword>
	<keyword>Dysuria</keyword>
	<keyword>Frequency</keyword>
	<keyword>Pain</keyword>
	<keyword>Uncomplicated Urinary Tract Infection</keyword>
	<keyword>Uncomplicated UTI</keyword>
	<keyword>Urinary Tract Infection</keyword>
	<keyword>UTI</keyword>
	<keyword>Burning urination associate uncomplicated urinary tract infection</keyword>
	<keyword>Urination frequency associate uncomplicated urinary tract infection</keyword>
	<keyword>Pain associate uncomplicated urinary tract infection</keyword>
</DOC>